Why Angiotensinogen Is the Upstream RAAS Target That Matters in Resistant Hypertension

Angiotensinogen (AGT) is the sole precursor of all angiotensin peptides, produced predominantly in hepatocytes, and its cleavage by renin initiates the renin-angiotensin-aldosterone system (RAAS) cascade. Hepatic AGT concentration is rate-limiting for angiotensin II generation — making it a mechanistically superior intervention point compared with ACE inhibitors or ARBs, which trigger a compensatory renin rise that partially offsets their antihypertensive effect. Upstream RNAi silencing of AGT eliminates that escape mechanism entirely.

Resistant hypertension is defined as blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes, including a diuretic. Its prevalence is estimated at 10–15% of the treated hypertension population. Among the pathophysiologic drivers identified in retrieved literature, aldosterone excess stands out: primary aldosteronism is found in 20–30% of patients with resistant hypertension, alongside heightened sympathetic nervous system activity and sodium retention.

The mechanistic rationale for AGT targeting in resistant hypertension is particularly compelling. Conventional RAAS blockers — ACE inhibitors, ARBs, and even direct renin inhibitors — all act downstream of AGT and face the limitation of reactive renin upregulation. By contrast, RNAi-mediated silencing of hepatic AGT removes the substrate for the entire RAAS cascade, as documented in retrieved academic literature from NIH-indexed research. Pre-clinical data in retrieved records indicate that AGT reduction also reduces renal fibrosis markers and albuminuria in hypertensive animal models, suggesting potential renoprotective benefits beyond blood pressure lowering.

The GalNAc-siRNA delivery mechanism underpinning zilebesiran exploits the asialoglycoprotein receptor (ASGR1) expressed on hepatocyte surfaces. GalNAc conjugation reduces the effective dose of siRNA by 10-fold compared with unconjugated controls and enables durable gene silencing with quarterly or semi-annual dosing intervals — a property that directly addresses the medication adherence problem endemic in resistant hypertension management, as documented in the seminal GalNAc platform paper by Nair et al. (2014).

KARDIA Phase 2 Clinical Signals: What the Data Show

Zilebesiran demonstrated durable, dose-dependent blood pressure reductions in two Phase 2 trials — KARDIA-1 in mild-to-moderate hypertension and KARDIA-2 in uncontrolled hypertension on background antihypertensive therapy — establishing the clinical foundation for Phase 3 enrollment in resistant hypertension.

In KARDIA-1, 394 adults with mild-to-moderate hypertension were randomly assigned to receive subcutaneous doses of zilebesiran (150 mg, 300 mg, or 600 mg every 6 months, or 300 mg every 3 months) or placebo. At 3 months, zilebesiran produced placebo-adjusted reductions in 24-hour ambulatory systolic blood pressure ranging from −6.0 to −14.1 mmHg in a dose-dependent manner. A reduction in serum angiotensinogen of more than 90% was achieved with the 150 mg dose and was sustained throughout the study for all doses. Adverse events were described as generally mild.

“A reduction in serum angiotensinogen of more than 90% was achieved with the 150 mg dose and was sustained throughout the study for all doses — establishing durable upstream RAAS suppression as achievable with a single subcutaneous injection.”

KARDIA-2 extended the evidence base to patients with uncontrolled hypertension on stable background therapy — the population most directly analogous to resistant hypertension candidates. In this trial, 553 adults on ACE inhibitors/ARBs, calcium channel blockers, or thiazide diuretics received zilebesiran 150 mg or 300 mg every 6 months or placebo added to existing medication. Zilebesiran produced placebo-adjusted reductions in daytime ambulatory systolic blood pressure of −8.7 to −12.1 mmHg, sustained to 6 months. Serum AGT was again reduced by more than 90%.

Taken together, the KARDIA-1 and KARDIA-2 results established the clinical rationale for Phase 3 KARDIA trials (KARDIA-3 and KARDIA-4) now enrolling patients with resistant hypertension and high cardiovascular risk to support NDA/BLA filings globally. The Alnylam–Roche collaboration, established in 2018, divides commercialization rights geographically: Alnylam retains US rights while Roche holds rights outside the United States.

Patent Landscape: Alnylam’s IP Strategy and Competitive Filings

Alnylam’s patent estate around zilebesiran is structured in overlapping layers — composition-of-matter claims on the siRNA sequences, chemical modification claims, GalNAc conjugation claims, and method-of-use claims explicitly covering resistant hypertension — creating a dense IP thicket that competitors must navigate.

The foundational composition filings include EP3452591B1 (granted, covering RNAi agents targeting AGT with GalNAc conjugation and specified chemical modifications including 2′-OMe, 2′-F, and phosphorothioate linkages) and the PCT application WO2017040493A1 (filed 2016, establishing early priority). US11389484B2 (granted 2022) covers methods of treating hypertension using AGT-targeting iRNA. These are supplemented by later filings including US20220323498A1 and US20230120273A1, which add claims on specific nucleotide modification patterns for enhanced stability and reduced immunogenicity.

Critically for the resistant hypertension indication, US20230348920A1 and US20230398123A1 explicitly claim methods of reducing systolic and diastolic blood pressure in subjects with resistant hypertension via subcutaneous AGT-targeting siRNA, with dosing regimens of every 3 or every 6 months. WO2023220732A1 covers combination therapy with ACE inhibitors, ARBs, calcium channel blockers, diuretics, and beta-blockers — the precise drug classes used in resistant hypertension patients. This combination filing directly addresses the clinical scenario of add-on therapy that defines Phase 3 KARDIA enrollment criteria, according to PatSnap’s pharmaceutical intelligence platform.

Competitive patent activity is visible from at least three other assignees. Silence Therapeutics (US20210238607A1) claims siRNA molecules targeting AGT and other RAAS components using its AtuRNAi chemistry platform with GalNAc or lipid conjugation. Dicerna Pharmaceuticals/Novo Nordisk (US20220267762A1, US20230193279A1) discloses GalXC-Plus Dicer-substrate siRNA agents targeting AGT, with Novo Nordisk’s 2021 acquisition of Dicerna providing a well-resourced development pathway. Arrowhead Pharmaceuticals (WO2023192573A1) applies its TRiM (Targeted RNAi Molecule) platform to RAAS-targeting compositions, claiming resistant hypertension applications.

Competing Platforms: GalNAc-siRNA Challengers and Device-Based Alternatives

Zilebesiran faces competition from two distinct therapeutic modalities: other GalNAc-siRNA programs targeting AGT or upstream RAAS components, and catheter-based renal denervation (RDN) devices validated in sham-controlled trials for resistant hypertension.

GalNAc-siRNA Platform Competitors

The GalNAc-siRNA modality has been validated for cardiovascular indications by inclisiran (Leqvio), a GalNAc-conjugated siRNA targeting PCSK9 mRNA developed by Novartis/The Medicines Company, which achieved approval in Europe and the US for hypercholesterolemia with a twice-yearly subcutaneous administration schedule. This approval, documented in retrieved literature by Ray et al. (2020), represents a critical precedent for the zilebesiran program — confirming that regulatory agencies accept the GalNAc-siRNA modality for chronic cardiovascular disease management, as noted by the European Medicines Agency.

Within the AGT-targeting competitive space specifically:

• Silence Therapeutics — The AtuRNAi chemistry platform is applied to AGT and other RAAS components (US20210238607A1). Silence Therapeutics’ SLN360 program against Lp(a) achieved a 98% reduction in Lp(a) levels in Phase 1, demonstrating the potency of the platform for cardiovascular targets.
• Dicerna Pharmaceuticals / Novo Nordisk — The GalXC-Plus extended Dicer-substrate siRNA platform (US20230193279A1) enables high-potency AGT knockdown in hepatocytes at low doses. Novo Nordisk’s 2021 acquisition of Dicerna provides substantial commercial and development resources.
• Arrowhead Pharmaceuticals — The TRiM (Targeted RNAi Molecule) platform (WO2023192573A1) applies compact, chemically stabilized siRNA molecules with alternating 2′-OMe/2′-F patterning to RAAS targets including AGT, with resistant hypertension explicitly claimed.

Device-Based Competition: Renal Denervation

Catheter-based renal denervation (RDN) represents a distinct competitive threat for patients with resistant hypertension who prefer a procedural intervention or cannot tolerate additional pharmacologic agents. A systematic review of the SYMPLICITY HTN-3, RADIANCE-HTN SOLO/TRIO, and SPYRAL HTN-OFF/ON MED trials documented statistically significant reductions in ambulatory systolic blood pressure versus sham procedure of 3.9–9.4 mmHg across trials. The Recor Medical Paradise and Medtronic Symplicity Spyral systems are approved or under FDA review. Notably, the BP reduction magnitudes from RDN overlap with the lower end of zilebesiran’s KARDIA-2 efficacy range (−8.7 to −12.1 mmHg), positioning RDN as a viable alternative for a subset of resistant hypertension patients, particularly those with high medication burden, according to FDA device evaluation frameworks.

Existing Pharmacologic Standard of Care

The current pharmacologic standard for resistant hypertension is spironolactone, established as the preferred fourth-line agent by the PATHWAY-2 trial (Williams et al., 2015), which demonstrated that spironolactone reduced home systolic BP by 8.70 mmHg more than placebo. Finerenone, a non-steroidal selective mineralocorticoid receptor antagonist, offers improved cardiorenal outcomes and represents an emerging alternative. The combination of mineralocorticoid receptor antagonist therapy with upstream AGT inhibition via zilebesiran is described in retrieved literature as a theoretically attractive strategy addressing multiple pathophysiologic components simultaneously.

Combination Strategies and the Path to Phase 3 Approval

The Phase 3 KARDIA program is designed to generate the combination efficacy and safety data required for registration in resistant hypertension — a population defined by treatment failure on three or more agents — making add-on combination data the central regulatory deliverable.

WO2023220732A1, filed by Alnylam in 2023, describes methods of treating hypertension including resistant hypertension with an RNAi agent targeting angiotensinogen in combination with one or more antihypertensive agents selected from ACE inhibitors, ARBs, calcium channel blockers, diuretics, and beta-blockers. The patent explicitly references combination data from the KARDIA-2 Phase 2 clinical studies, suggesting the IP filing is closely coordinated with the clinical program to ensure that combination-use data generated in Phase 3 is covered by issued or pending claims.

The mechanistic rationale for combination therapy is particularly robust for zilebesiran versus conventional RAAS blockers. Because zilebesiran acts upstream of ACE inhibitors, ARBs, and direct renin inhibitors — removing the AGT substrate rather than blocking downstream enzymatic steps — it does not compete with these agents but rather amplifies their effect by eliminating the compensatory renin rise they provoke. Retrieved academic literature notes that upstream inhibition of AGT synthesis eliminates compensatory renin rises seen with ACE inhibitors and ARBs, a mechanism that makes zilebesiran a natural combination partner rather than a replacement for existing RAAS therapy.

The aldosterone pathway presents a specific combination opportunity. Primary aldosteronism is found in 20–30% of patients with resistant hypertension, and mineralocorticoid receptor antagonists (MRAs) including spironolactone and finerenone demonstrate superior blood pressure reduction in this population. Retrieved literature describes the combination of MRA therapy with upstream AGT inhibition as a theoretically attractive strategy addressing multiple pathophysiologic components of resistant hypertension simultaneously — a rationale that may inform future Phase 3 sub-group analyses or dedicated combination trials.

The regulatory path is informed by the inclisiran precedent: approval of a twice-yearly subcutaneous GalNAc-siRNA for a chronic cardiovascular indication established that European Medicines Agency and FDA accept long-acting RNAi therapeutics for cardiovascular disease management. The KARDIA-3 and KARDIA-4 Phase 3 trials are designed to generate the resistant hypertension–specific outcome data needed for label expansion beyond the milder hypertension populations studied in Phase 2. Detailed patent and trial monitoring is available through PatSnap’s pharmaceutical intelligence tools.